Ultragenyx Wins Sanfilippo Type A Approval & Xenon Pauses New Psychiatry Enrollment

Ultragenyx has FDA approval for Fayuvi in Sanfilippo syndrome type A. Children gain a treatment option, with eligibility limited to those whose neurodevelopmental function is preserved.

Also today, Roche's Lunsumio combination hits its Phase 3 goal in CELESTIMO. And Xenon files in epilepsy while pausing new psychiatry enrollment for the same drug.

Welcome to The Pharma Closeout for Thursday, September 17th. I'm Alex Mercer.

And I'm Maya Patel. Today, we'll connect the treatment choices these stories could open with the evidence and access hurdles that still shape them.

Our top story is Fayuvi, Ultragenyx's one-time intravenous gene therapy for Sanfilippo syndrome type A, also called MPS IIIA. FDA approved it today for neurologic manifestations in children with preserved neurodevelopmental function. This fatal disease progressively takes away cognitive, language and motor abilities, starting in early childhood. FDA calls Fayuvi the first treatment for these pediatric patients. That changes the choices available, but the preserved-function requirement is a consequential boundary.

The indication doesn't cover every child with the disease, and it doesn't promise to restore abilities already lost. The evidence compares 17 treated children with 27 untreated children from an external natural-history group. Their developmental trajectories separated, but those children weren't randomized alongside one another.

What does that separation tell us about the benefit?

The adjusted difference was 23.5 points on the Bayley-III cognitive raw score, favoring treatment. The label's comparison follows changes in that score from ages two to five. It supports a different cognitive trajectory from the untreated comparison. It doesn't tell us which skills an individual child will retain or recover. Differences between these small, separately assembled groups remain a limitation.

The label's boundary also raises an access question. In a progressive disease, identifying and referring children while function remains becomes especially important. Ultragenyx isn't building a commercial organization from scratch: it already markets rare-disease medicines. Fayuvi follows the company's preceding gene-therapy approval in August. But getting this treatment to an eligible child requires a qualified gene-therapy center, not simply another prescription.

And one infusion still comes with substantial care around it. Corticosteroids start before treatment and continue afterward, with liver-function and platelet monitoring. Hepatotoxicity and thrombocytopenia are among the label warnings. Those requirements belong in the access picture because the center needs to manage the treatment and its follow-up, not just administer the dose.

Ultragenyx expects product to be available for shipment to qualified U.S. centers within thirty to sixty days. That's its shipment timetable, not a confirmed first-treatment date. The company says it's working with centers and payers on access. The next practical test is whether that network can turn this restricted approval into treatment while children remain eligible. We don't yet have launch uptake or coverage results to judge that.

First in the deal roundup, Lisata completed its stock-for-stock acquisition of Marea today. It also signed a separate private financing for roughly $225 million gross, expected to close on September 18th, subject to conditions. That money is new financing, not the purchase price. The combination redirects the listed company toward Marea's metabolic and endocrine pipeline.

One anchor is MAR001/005, in Phase 2b for severe hypertriglyceridemia. The company expects its topline data in the fourth quarter of 2027.

And the ownership tells you how extensive the reset is. Legacy Lisata holders are projected to own 2.39% on a fully diluted, as-converted basis. The preferred-stock conversion still needs stockholder approval. Management projects runway into 2028, beyond that planned readout. If the financing closes as expected, it gives the new pipeline time to produce evidence.

Separately, Roche is paying Dualitas $36.5 million upfront for bispecific discovery in immunology and inflammation. Dualitas's DualScreen platform will screen more than 300,000 bispecific combinations, with Roche taking responsibility after discovery. Contingent milestones bring the total potential value to as much as $1 billion, including the upfront payment. Tiered royalties sit on top. The committed capital buys access to discovery work; most of the headline value depends on later milestones.

No partnered target or candidate was named. This adds a discovery relationship to Roche's pipeline-building efforts, with no partnered clinical result yet to assess.

On the pipeline side, Longeveron's stem-cell therapy laromestrocel missed its primary endpoint in infants with hypoplastic left heart syndrome. ELPIS II tested the treatment during the second stage of heart surgery for this severe congenital defect, against surgery alone. The randomized Phase 2b study enrolled forty infants and assessed right-ventricular ejection fraction at twelve months.

The estimated between-group difference was minus 0.7 percentage points. The company also points to exploratory cardiovascular-event findings, but those weren't statistically significant. They can inform the company's further analyses; they don't reverse the primary result or establish a survival benefit. That's particularly important when a small study produces several ways to look at the outcomes.

Longeveron plans further analyses and an FDA discussion. The announcement doesn't describe an agreed regulatory path. The unresolved issue is what evidence could support continued development after this trial failed its prespecified efficacy test.

In Regulatory Watch, Xenon submitted its focal-seizure application for azetukalner today. Separately, it voluntarily paused new enrollment in studies of the same drug for major depressive disorder and bipolar depression. That followed a review of neuropsychiatric adverse events. Patients already enrolled remain active, and epilepsy studies continue enrolling. The company hasn't announced FDA acceptance or a review date for the seizure application.

The epilepsy filing and psychiatry expansion now face different questions. What has Xenon disclosed about the events behind that enrollment pause?

Xenon says the events were consistent with the drug's known profile, but the announcement gives no event counts, named event types or severity breakdown. In the depression study X-NOVA2, current patients will finish dosing before the data are unblinded. Xenon expects topline results in the first quarter of 2027.

The epilepsy filing itself rests on placebo-controlled evidence, including Phase 3 X-TOLE2. Psychiatry remains a separate expansion opportunity with a safety question still unresolved. The filing doesn't answer that question, and the enrollment pause doesn't settle the epilepsy application's outcome.

Next, Bayer says FDA approved Kerendia, the once-daily oral medicine finerenone, for adults with chronic kidney disease associated with type 1 diabetes. The indication targets reduction in urinary albumin-to-creatinine ratio, with an expected reduction in subsequent kidney risk. In FINE-ONE, involving 242 adults, that ratio fell 25% relative to placebo over six months.

Bayer calls this Kerendia's third U.S. indication. It expands the population the medicine can serve, but the wording of the benefit deserves care. How much of that kidney protection was actually observed in this trial?

The trial directly measured albuminuria. Bayer's approval announcement describes the longer-term kidney benefit as expected. That expectation rests on the albuminuria result; the trial didn't measure fewer kidney-failure events in this type 1 diabetes population.

In England, NICE says around a thousand eligible people can now be offered Enhertu for routine NHS use. Its recommendation for HER2-low advanced breast cancer is final draft guidance, with the appeal window open through October 7th. NICE describes access from today, September 17th, even as that procedural step remains open.

This is an access change for AstraZeneca and Daiichi Sankyo's medicine. NICE says a commercial solution and changes to its appraisal methods enabled the recommendation after the earlier price impasse. The financial terms aren't public. What changed here is the reimbursement decision, not the drug's clinical result.

The population remains specific: prior chemotherapy for metastatic disease, or recurrence during or within six months of adjuvant chemotherapy. That leaves a defined group with a new access route in England, rather than everyone with HER2-low disease.

One more regulatory item: Aquestive resubmitted its application for Anaphylm, a sublingual epinephrine-prodrug film candidate for anaphylaxis. The company says it addressed packaging and administration issues from January's complete response letter, with human-factors and confirmatory pharmacokinetic work. Revised packaging cut median pouch-opening time from seventeen seconds to three in the sponsor's testing. The pharmacokinetic study used healthy volunteers.

For an emergency-use product, opening the pouch is part of the delivery question. Aquestive's response gives FDA usability and pharmacokinetic evidence to review. Those tests don't establish effectiveness during anaphylaxis. Aquestive hasn't announced acceptance, classification or a new review date.

Quick note before our second top story today — if The Pharma Closeout is how you close out your day, follow the show on Spotify or Apple Podcasts.

Our second top story is Roche's CELESTIMO trial: Lunsumio plus lenalidomide met its Phase 3 progression-free-survival endpoint in relapsed or refractory follicular lymphoma. Lunsumio's current U.S. approval is an accelerated approval for monotherapy after at least two prior systemic treatments. This combination trial enrolled patients after at least one. Genentech announced the result yesterday; Roche's global release followed today. It could support full approval and an earlier-line indication.

The comparator gives that result weight: intravenous Lunsumio with oral lenalidomide was tested against rituximab plus lenalidomide. But Roche hasn't released the size of the progression-free-survival benefit from this interim analysis, and overall survival is immature. How much longer it held the disease back is still missing.

That's the missing piece for competition. Genmab's Epkinly and Incyte's Monjuvi already have U.S. approvals with rituximab and lenalidomide in relapsed or refractory follicular lymphoma. Roche would enter that earlier-line discussion with two drugs rather than those three-drug regimens.

Fewer drugs doesn't establish easier treatment or better tolerability. Roche reports no new safety signals, but the combination's detailed safety data haven't been released either.

The label hasn't changed. Roche has a positive confirmatory trial to take into its intended regulatory submission. The detailed efficacy and safety results will show how strong a case it can make for this regimen.

That's today's closeout. Fayuvi makes an approved treatment possible for a narrowly defined group of children. Lunsumio's next chapter still depends on the details behind its trial headline.

Thanks for spending part of your Thursday with us. Have a good evening.

Follow the show on Apple Podcasts, Spotify, or wherever you listen — a quick rating or share helps other listeners find us. We'll bring you updates as these stories develop.